Navigation Links
Cequent Pharmaceuticals' Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
Date:4/30/2008

CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that its Vice President of Research, Johannes Fruehauf, MD, Ph.D., is slated to speak at the RNAi World Congress meeting in Boston. His presentation, "Treatment of Gastrointestinal Targets using RNA Interference," is scheduled for 4:25 pm on Friday, May 2, at the Hilton Boston Logan Airport. Dr. Fruehauf is co-inventor of Cequent's proprietary TransKingdom RNA interference (tkRNAi(TM)) technology, designed to solve one of the key challenges to RNAi therapeutics -- delivery of the RNAi into the cell.

Cequent's goal with its first clinical candidate is to prevent polyp formation in patients with a high risk of developing colon cancer. In his talk, Dr. Fruehauf will give an overview of the company's preclinical-development program for the therapeutic, presenting efficacy data in mouse models and data on a major monkey toxicology study currently under way. The latter is the first study evaluating the safety and efficacy of tkRNAi in a non-human primate model -- an important step for Cequent in the development of tkRNAi-based drugs for human disease. In addition, Dr. Fruehauf will introduce Cequent's programs for inflammatory bowel disease (IBD) and human Papilloma virus (HPV), which targets cervical cancer.

Dr. Fruehauf's participation in the RNAi World Congress follows Cequent presentations at two other high-profile conferences. In March, Dr. Fruehauf introduced tkRNAi and its application in cancer prevention targeting beta-catenin at the Keystone Symposium on RNAi, MicroRNA, and Non-Coding RNA in Whistler, British Columbia. Cequent's Associate Director of RNAi Research, Jens Harborth, Ph.D., also presented at the conference, discussing the company's unique algorithm of developing tkRNAi target sequences, which are active across species. This approach allows
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
2. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
3. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
4. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
5. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
9. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
10. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
11. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Pressure BioSciences, Inc. (OTCQB: ... has received and approved all parts required to ... has begun to manufacture the new PCT-based instrument ... be ready for shipment by mid-October and that ... at a rate of about one per week ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
(Date:9/19/2014)... -- PCI is pleased to announce it has acquired ... provider of Clinical Trial Services and Temperature Controlled ... in the United Kingdom ... in the UK/EU to support global investigational studies ... distribution capacity, as well as consultative services for ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6
(Date:9/20/2014)... The first federal bellwether trial of ... third week in the U.S. District Court, Northern District ... indicate that the week opened in the DePuy ... DePuy Orthopaedics vice president, who discussed the clinical testing ... hip replacement. According to Reuters, the executive stated that ...
(Date:9/20/2014)... Nevada (PRWEB) September 20, 2014 ... extremely successful showing at the PAIN Week conference ... Cosmopolitan Hotel and Casino in Las Vegas from ... MarijuanaDoctors.com primarily attended PAIN Week in the hopes ... as a viable and legitimate tool to treat ...
(Date:9/19/2014)... (PRWEB) September 20, 2014 Nearly 780 ... of Common Pleas where a meeting took place to ... complaints pending in the court’s mass tort program. ... meet this past week at the Complex Litigation Center ... consolidated for pretrial proceedings. The Risperdal lawsuits filed against ...
(Date:9/19/2014)... DC) (PRWEB) September 19, 2014 “Copay ... inflate sales of brand drugs among patients with prescription ... according to a new report from the ... Inspector General (OIG). Federal anti-kickback laws prohibit suppliers from ... subsidized by the federal government. , The report highlights ...
(Date:9/19/2014)... September 19, 2014 Unbound , an ... families in regions of the Philippines being affected by both ... than 1,060 families evacuated to the nearest public schools while ... heavy rain and gusty winds to portions of the northern ... flooding. Some homes filled with more than 10 feet of ...
Breaking Medicine News(10 mins):Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2
... egg should be avoided by patients with high cholesterol ... has developed a egg variety that does no ... diabetes is growing especially in Indian sub-continent. 'The modified ... S.K. Taneja, a professor in the university's Department of ...
... are increasingly recognized as important factors in disease ... drug resistance. However, the distinction of co-infecting site ... been // ficult with traditional methods based on ... ,Trypanosoma brucei , a protozoan parasite transmitted by ...
... can be used to reveal the strength of bones ... the likelihood of fracturing a particular bone, an article ... says. ,Scientists have developed a laser imaging technique ... density thereby predicting future risk of fracturing that particular ...
... from Italy have found a new urine test which detects ... test which is proved to be 90% accurate is used ... of patients. The results of the study have been published ... would be very useful for detecting cancer in smokers and ...
... perception is dependent on the specialized cells of the eye. ... a research state that our perception of color is controlled ... ,The number of color-sensitive cones in the human retina differs ... perceive colors the same way. The study has shown that ...
... In a novel initiative to combat the spread of ... joint initiative// of the William J. Clinton Foundation and ... entered into a partnership with Nickelodeon's award-winning Let's Just ... forces on a comprehensive media and public awareness campaign, ...
Cached Medicine News:Health News:Fluorescent markers to distinguish Trypanosoma brucei strains causing Sleeping Sickness 2Health News:Urine testing for telomerase enzyme for bladder cancer diagnosis 2Health News:Seeing Is Believing Does Not Hold Good For Color Perception 2Health News:A New Initiative To Fight Childhood Obesity 2
2 mm wide x 3 mm long, tapered handle. Angled 45 degrees. Round handle....
1.5 mm long blade. Square handle....
3 mm diameter roller blade in line with handle. Curved shaft. Flat handle. 15 mm from curve to tip....
2 mm wide x 3 mm long, with rounded triangular tip. Angled 45 degrees. Hexagonal handle....
Medicine Products: